Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2017
Quantitative Assessment of Early [
Abstract readClinical TrialMulticenter Study
In one paragraph
Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
6.7field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 61 citations in OpenAlex.
- Comparison of PSMA-PET/CT, choline-PET/CT, NaF-PET/CT, MRI, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a systematic review and meta-analysis.Skeletal radiology · 2019Pooled it
- Whole-Body [Tomography (Ann Arbor, Mich.) · 2021Trial
- Trial
- Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP [MVI-816]) in Patients With Progressive, Nonmetastatic, Castration-Sensitive Prostate Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2019Trial
- Prediction of therapy response in bone-predominant metastatic breast cancer: comparison of [European journal of nuclear medicine and molecular imaging · 2019Trial
- Advanced Image Analysis to Select Patients for Prostate Specific Membrane Antigen Radioligand Therapy and Assess Treatment Response.Advances in radiation oncology · 2025Article
- Full-Body Tumor Response Heterogeneity of Metastatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radiopharmaceutical Therapy.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- Quantitative evaluation of lesion response heterogeneity for superior prognostication of clinical outcome.European journal of nuclear medicine and molecular imaging · 2024Article
- Uncertainty quantification via localized gradients for deep learning-based medical image assessments.Physics in medicine and biology · 2024Article
- Performance of an automated registration-based method for longitudinal lesion matching and comparison to inter-reader variability.Physics in medicine and biology · 2023Article
- Automated quantification of PET/CT skeletal tumor burden in prostate cancer using artificial intelligence: The PET index.European journal of nuclear medicine and molecular imaging · 2023Article
- The value ofFrontiers in bioengineering and biotechnology · 2022Article
- Current and future targeted alpha particle therapies for osteosarcoma: Radium-223, actinium-225, and thorium-227.Frontiers in medicine · 2022Review
- Review
- Determination and clinical significance of bone pseudoprogression in hormone receptor-positive metastatic breast cancer.Therapeutic advances in medical oncology · 2021Article
- Recent updates and developments in PET imaging of prostate cancer.Abdominal radiology (New York) · 2020Review
- Measuring the unmeasurable: automated bone scan index as a quantitative endpoint in prostate cancer clinical trials.Prostate cancer and prostatic diseases · 2019Review
- Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2019Article
- Impact of Anatomic Location of Bone Metastases on Prognosis in Metastatic Castration-Resistant Prostate Cancer.Clinical genitourinary cancer · 2019Article
- Treatment Response Assessment of Skeletal Metastases in Prostate Cancer withNuclear medicine and molecular imaging · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Stephanie A HarmonStephanie A. Harmon, Timothy Perk, Christie Lin, Jens Eickhoff, Glenn Liu, and Robert Jeraj, University of Wisconsin-Madison; Glenn Liu and Robert Jeraj, Prostate Cancer Clinical Trials Consortium, Madison, WI; Peter L. Choyke, William L. Dahut, and Andrea B. Apolo, National Cancer Institute, Bethesda, MD; John L. Humm, Steven M. Larson, and Michael J. Morris, Memorial Sloan Kettering Cancer Center; and Steven M. Larson and Michael J. Morris, Prostate Cancer Clinical Trials Consortium, New York, NY.
Timothy PerkStephanie A. Harmon, Timothy Perk, Christie Lin, Jens Eickhoff, Glenn Liu, and Robert Jeraj, University of Wisconsin-Madison; Glenn Liu and Robert Jeraj, Prostate Cancer Clinical Trials Consortium, Madison, WI; Peter L. Choyke, William L. Dahut, and Andrea B. Apolo, National Cancer Institute, Bethesda, MD; John L. Humm, Steven M. Larson, and Michael J. Morris, Memorial Sloan Kettering Cancer Center; and Steven M. Larson and Michael J. Morris, Prostate Cancer Clinical Trials Consortium, New York, NY.
Christie LinStephanie A. Harmon, Timothy Perk, Christie Lin, Jens Eickhoff, Glenn Liu, and Robert Jeraj, University of Wisconsin-Madison; Glenn Liu and Robert Jeraj, Prostate Cancer Clinical Trials Consortium, Madison, WI; Peter L. Choyke, William L. Dahut, and Andrea B. Apolo, National Cancer Institute, Bethesda, MD; John L. Humm, Steven M. Larson, and Michael J. Morris, Memorial Sloan Kettering Cancer Center; and Steven M. Larson and Michael J. Morris, Prostate Cancer Clinical Trials Consortium, New York, NY.
Jens EickhoffStephanie A. Harmon, Timothy Perk, Christie Lin, Jens Eickhoff, Glenn Liu, and Robert Jeraj, University of Wisconsin-Madison; Glenn Liu and Robert Jeraj, Prostate Cancer Clinical Trials Consortium, Madison, WI; Peter L. Choyke, William L. Dahut, and Andrea B. Apolo, National Cancer Institute, Bethesda, MD; John L. Humm, Steven M. Larson, and Michael J. Morris, Memorial Sloan Kettering Cancer Center; and Steven M. Larson and Michael J. Morris, Prostate Cancer Clinical Trials Consortium, New York, NY.
Peter L ChoykeStephanie A. Harmon, Timothy Perk, Christie Lin, Jens Eickhoff, Glenn Liu, and Robert Jeraj, University of Wisconsin-Madison; Glenn Liu and Robert Jeraj, Prostate Cancer Clinical Trials Consortium, Madison, WI; Peter L. Choyke, William L. Dahut, and Andrea B. Apolo, National Cancer Institute, Bethesda, MD; John L. Humm, Steven M. Larson, and Michael J. Morris, Memorial Sloan Kettering Cancer Center; and Steven M. Larson and Michael J. Morris, Prostate Cancer Clinical Trials Consortium, New York, NY.
William L DahutStephanie A. Harmon, Timothy Perk, Christie Lin, Jens Eickhoff, Glenn Liu, and Robert Jeraj, University of Wisconsin-Madison; Glenn Liu and Robert Jeraj, Prostate Cancer Clinical Trials Consortium, Madison, WI; Peter L. Choyke, William L. Dahut, and Andrea B. Apolo, National Cancer Institute, Bethesda, MD; John L. Humm, Steven M. Larson, and Michael J. Morris, Memorial Sloan Kettering Cancer Center; and Steven M. Larson and Michael J. Morris, Prostate Cancer Clinical Trials Consortium, New York, NY.
Andrea B ApoloStephanie A. Harmon, Timothy Perk, Christie Lin, Jens Eickhoff, Glenn Liu, and Robert Jeraj, University of Wisconsin-Madison; Glenn Liu and Robert Jeraj, Prostate Cancer Clinical Trials Consortium, Madison, WI; Peter L. Choyke, William L. Dahut, and Andrea B. Apolo, National Cancer Institute, Bethesda, MD; John L. Humm, Steven M. Larson, and Michael J. Morris, Memorial Sloan Kettering Cancer Center; and Steven M. Larson and Michael J. Morris, Prostate Cancer Clinical Trials Consortium, New York, NY.
John L HummStephanie A. Harmon, Timothy Perk, Christie Lin, Jens Eickhoff, Glenn Liu, and Robert Jeraj, University of Wisconsin-Madison; Glenn Liu and Robert Jeraj, Prostate Cancer Clinical Trials Consortium, Madison, WI; Peter L. Choyke, William L. Dahut, and Andrea B. Apolo, National Cancer Institute, Bethesda, MD; John L. Humm, Steven M. Larson, and Michael J. Morris, Memorial Sloan Kettering Cancer Center; and Steven M. Larson and Michael J. Morris, Prostate Cancer Clinical Trials Consortium, New York, NY.
Steven M LarsonStephanie A. Harmon, Timothy Perk, Christie Lin, Jens Eickhoff, Glenn Liu, and Robert Jeraj, University of Wisconsin-Madison; Glenn Liu and Robert Jeraj, Prostate Cancer Clinical Trials Consortium, Madison, WI; Peter L. Choyke, William L. Dahut, and Andrea B. Apolo, National Cancer Institute, Bethesda, MD; John L. Humm, Steven M. Larson, and Michael J. Morris, Memorial Sloan Kettering Cancer Center; and Steven M. Larson and Michael J. Morris, Prostate Cancer Clinical Trials Consortium, New York, NY.
Michael J MorrisStephanie A. Harmon, Timothy Perk, Christie Lin, Jens Eickhoff, Glenn Liu, and Robert Jeraj, University of Wisconsin-Madison; Glenn Liu and Robert Jeraj, Prostate Cancer Clinical Trials Consortium, Madison, WI; Peter L. Choyke, William L. Dahut, and Andrea B. Apolo, National Cancer Institute, Bethesda, MD; John L. Humm, Steven M. Larson, and Michael J. Morris, Memorial Sloan Kettering Cancer Center; and Steven M. Larson and Michael J. Morris, Prostate Cancer Clinical Trials Consortium, New York, NY.
Glenn LiuStephanie A. Harmon, Timothy Perk, Christie Lin, Jens Eickhoff, Glenn Liu, and Robert Jeraj, University of Wisconsin-Madison; Glenn Liu and Robert Jeraj, Prostate Cancer Clinical Trials Consortium, Madison, WI; Peter L. Choyke, William L. Dahut, and Andrea B. Apolo, National Cancer Institute, Bethesda, MD; John L. Humm, Steven M. Larson, and Michael J. Morris, Memorial Sloan Kettering Cancer Center; and Steven M. Larson and Michael J. Morris, Prostate Cancer Clinical Trials Consortium, New York, NY.
Robert JerajStephanie A. Harmon, Timothy Perk, Christie Lin, Jens Eickhoff, Glenn Liu, and Robert Jeraj, University of Wisconsin-Madison; Glenn Liu and Robert Jeraj, Prostate Cancer Clinical Trials Consortium, Madison, WI; Peter L. Choyke, William L. Dahut, and Andrea B. Apolo, National Cancer Institute, Bethesda, MD; John L. Humm, Steven M. Larson, and Michael J. Morris, Memorial Sloan Kettering Cancer Center; and Steven M. Larson and Michael J. Morris, Prostate Cancer Clinical Trials Consortium, New York, NY.
Memorial Sloan Kettering Cancer Center · US
Funding
UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Christian Capitini · 1985 to 2026
$142.6MDisparities in COVID Disease Severity and Outcomes in New York CityUL1TR002384 · NCATS · WEILL MEDICAL COLL OF CORNELL UNIV · PI JULIANNE L IMPERATO-MCGINLEY · 2017 to 2026
$86.2MProstate Cancer ImagingZIABC010655 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI CHOYKE, PETER L · 2009 to 2025
$49.2MU.W. RADIOLOGICAL SCIENCES TRAINING PROGRAMT32CA009206 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Bryan Patrick Bednarz · 1985 to 2026
$12.1MBladder Cancer ProgramZIABC011351 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI APOLO, ANDREA · 2010 to 2025
$9.4MNCATS NIH HHS UL1 TR002384NCI NIH HHS P30 CA014520NCI NIH HHS T32 CA009206
Abstract
Purpose [
Indexed as
AgedAndrogen Receptor AntagonistsBone NeoplasmsDisease-Free SurvivalDocetaxelFluorine RadioisotopesHumansMalePositron Emission Tomography Computed TomographyProspective StudiesProstatic Neoplasms, Castration-ResistantSodium FluorideTaxoidsTreatment OutcomeAndrogen Receptor AntagonistsDocetaxelFluorine RadioisotopesSodium FluorideTaxoids
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.